Page 129 - 《中国药房》2024年11期
P. 129

中药调控p53信号通路干预肺癌的作用机制研究进展
                                                                                           Δ


                                     1, 2
                                              1, 2
          马 倩    1, 2* ,李 亚 ,马艺钊 ,陈 锴 ,王元元              1, 2, 3 ,张海龙  1, 2, 3 # (1.河南中医药大学第一附属医院呼吸与危
                           1, 2
          重症医学科,郑州 450003;2.河南中医药大学第一临床医学院,郑州 450003;3.河南中医药大学呼吸疾病中
          医药防治省部共建协同创新中心/河南省中医药防治呼吸病重点实验室,郑州 450046)


          中图分类号  R965;R285.5      文献标志码  A      文章编号  1001-0408(2024)11-1403-05
          DOI  10.6039/j.issn.1001-0408.2024.11.21

          摘  要  肺癌是最常见的恶性肿瘤,其发病机制复杂、恶性程度高,严重威胁了患者的生命健康。p53信号通路是影响肺癌进程的
          重要通路,被众多研究者视为肺癌靶向治疗的潜在靶点之一。近年来,已有较多研究深入探讨了中药调控p53信号通路干预肺癌
          的可行性。基于此,本文系统总结了中药调控p53信号通路干预肺癌的作用机制研究进展,发现清金得生片、调气消积汤、补肺通
          络解毒方、健脾补肾方及益气扶正解毒方等中药复方及制剂可通过激活p53信号通路,促进肺癌细胞自噬及凋亡,抑制肺癌细胞
          生长及转移,增强机体免疫功能,发挥抑癌作用;拟人参皂苷Rh2、柴胡皂苷D、重楼皂苷Ⅶ、石斛碱、槐定碱、藤黄酸、雷公藤甲素及
          雷公藤甲素丁二酸单酯YJ-4等中药单体可通过激活p53信号通路,促进肺癌细胞凋亡,抑制肺癌细胞增殖,调控肺癌细胞周期,发
          挥抑癌作用。
          关键词  肺癌;p53信号通路;作用机制;中药;有效成分

          Mechanism research progress of traditional Chinese medicine intervening in lung cancer by regulating p53
          signaling pathway
                                                      1, 2
                  1, 2
                           1, 2
                                         1, 2
          MA Qian ,LI Ya ,MA Yizhao ,CHEN Kai ,WANG Yuanyuan             1, 2, 3 ,ZHANG Hailong 1, 2, 3 (1.  Dept.  of
          Respiratory  and  Critical  Care  Medicine,  the  First Affiliated  Hospital  of  Henan  University  of  Chinese  Medicine,
          Zhengzhou  450003,  China;2.  First  College  of  Clinical  Medicine,  Henan  University  of  Chinese  Medicine,
          Zhengzhou  450003,  China;3.  Collaborative  Innovation  Center  for  Chinese  Medicine  and  Respiratory  Diseases
          Co-constructed  by  Henan  Province  &  Education  Ministry  of  P. R.  China/Henan  Key  Laboratory  of  Chinese
          Medicine for Respiratory Disease, Henan University of Chinese Medicine, Zhengzhou 450046, China)

          ABSTRACT   Lung cancer, the most common malignant tumor, is characterized by a complex pathogenesis and high malignancy,
          and  poses  a  significant  threat  to  the  health  and  lives  of  affected  individuals.  p53  signaling  pathway  plays  a  crucial  role  in  the
          progression of lung cancer and is considered one of the potential targets for targeted therapy. In recent years, multiple studies have
          indicated that traditional Chinese medicine (TCM) can exert anticancer effects by modulating the p53 signaling pathway. Based on
          this,  this  article  systematically  summarizes  the  current  status  and  progress  of  research  on  TCM  intervening  in  lung  cancer  by
          regulating  p53  signaling  pathway.  It  was  found  that  TCM  formula  and  preparations,  such  as  Qingjin  desheng  tablet,  Tiaoqi  xiaoji
          decoction,  Bufei  tongluo  jiedu  formula,  Jianpi  bushen  formula  and  Yiqi  fuzheng  jiedu  formula,  can  promote  autophagy  and
          apoptosis  of  lung  cancer  cells,  inhibit  the  growth  and  metastasis  of  lung  cancer  cells  and  strengthen  the  immune  function  of  the
          body  by  activating  p53  signaling  pathway,  thereby  inhibiting  lung  cancer.  TCM  monomers,  such  as  pseudoginsenoside-Rh2,
          saikosaponin D, polyphyllin Ⅶ, dendrobiine, sophoridine, gambogic acid, triptolide and triptolide succinate monoester YJ-4, can
          accelerate  cell  apoptosis,  inhibit  the  proliferation  of  lung  cancer  cells  and  regulate  cell  cycle  by  activating  p53  signaling  pathway,
          thereby inhibiting lung cancer.
          KEYWORDS    lung cancer; p53 signaling pathway; mechanism; traditional Chinese medicine; effective components


                                                                 肺癌是一种源自呼吸道上皮细胞的恶性肿瘤,根据

             Δ 基金项目 河南省中医药科学研究专项课题(No.2021JDZX-              组织病理学特点,可分为非小细胞肺癌(non-small cell
                                                                                            [1]
          2009)                                              lung cancer,NSCLC)和小细胞肺癌 。相关研究显示,
             *第一作者 硕士研究生。研究方向:呼吸疾病的中医药防治与评                   全球每年新增确诊肺癌患者 220 万左右,约 179 万患者
          价。E-mail:a15886751333@163.com
                                                             因肺癌死亡,肺癌已成为目前癌症相关死亡率最高的癌
             # 通信作者 教授,博士生导师,博士。研究方向:呼吸疾病的中医
                                                                                              [2]
          药防治与评价。E-mail:zhanghailong@126.com                 症病种,严重威胁国民健康及生活质量 。目前,肺癌的

          中国药房  2024年第35卷第11期                                              China Pharmacy  2024 Vol. 35  No. 11    · 1403 ·
   124   125   126   127   128   129   130   131   132   133   134